Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 4
1979 13
1980 23
1981 69
1982 136
1983 70
1984 90
1985 151
1986 267
1987 474
1988 666
1989 788
1990 821
1991 778
1992 750
1993 722
1994 656
1995 614
1996 586
1997 464
1998 441
1999 407
2000 391
2001 356
2002 353
2003 308
2004 255
2005 260
2006 218
2007 223
2008 221
2009 216
2010 187
2011 207
2012 205
2013 161
2014 172
2015 126
2016 143
2017 112
2018 94
2019 78
2020 88
2021 88
2022 79
2023 75
2024 35

Search Results

13,312 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin-2 toxicity.
Siegel JP, Puri RK. Siegel JP, et al. J Clin Oncol. 1991 Apr;9(4):694-704. doi: 10.1200/JCO.1991.9.4.694. J Clin Oncol. 1991. PMID: 2066765 Review.
Interleukin-2 and leukemia.
Goodman M, Cabral L, Cassileth P. Goodman M, et al. Leukemia. 1998 Nov;12(11):1671-5. doi: 10.1038/sj.leu.2401199. Leukemia. 1998. PMID: 9823939 Review.
Therapeutic potential of interleukin-2 in autoimmune diseases.
Yuan Y, Kolios AGA, Liu Y, Zhang B, Li H, Tsokos GC, Zhang X. Yuan Y, et al. Trends Mol Med. 2022 Jul;28(7):596-612. doi: 10.1016/j.molmed.2022.04.010. Epub 2022 May 24. Trends Mol Med. 2022. PMID: 35624009 Review.
Recombinant interleukin-2.
Bruton JK, Koeller JM. Bruton JK, et al. Pharmacotherapy. 1994 Nov-Dec;14(6):635-56. Pharmacotherapy. 1994. PMID: 7885967 Review.
Interleukin 2.
Hamblin TJ. Hamblin TJ. BMJ. 1990 Feb 3;300(6720):275-6. doi: 10.1136/bmj.300.6720.275. BMJ. 1990. PMID: 2106954 Free PMC article. Review. No abstract available.
Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.
Lim TY, Perpiñán E, Londoño MC, Miquel R, Ruiz P, Kurt AS, Kodela E, Cross AR, Berlin C, Hester J, Issa F, Douiri A, Volmer FH, Taubert R, Williams E, Demetris AJ, Lesniak A, Bensimon G, Lozano JJ, Martinez-Llordella M, Tree T, Sánchez-Fueyo A. Lim TY, et al. J Hepatol. 2023 Jan;78(1):153-164. doi: 10.1016/j.jhep.2022.08.035. Epub 2022 Sep 7. J Hepatol. 2023. PMID: 36087863 Free article. Clinical Trial.
Managing toxicities of high-dose interleukin-2.
Schwartz RN, Stover L, Dutcher JP. Schwartz RN, et al. Oncology (Williston Park). 2002 Nov;16(11 Suppl 13):11-20. Oncology (Williston Park). 2002. PMID: 12469935 Free article. Review.
13,312 results
You have reached the last available page of results. Please see the User Guide for more information.